Stockpolly
Search
MOLN · NASDAQ · Biotechnology

Molecular Partners (ADR) (MOLN)

Develops DARPin cancer therapies, including Radio-DARPins and immune-cell engagers.

$4.24
Pre-market+0.03 (+0.65%)
At close$4.21(−1.75%)
Watchlist

In millions of USD, except per-share figures · converted from CHF at the latest rate

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue313210000000
Cost of revenue1415171613121011121
Gross profit−11−13−14−14−13−12−10−1−1−12−1
207655721211819516
Research & development14161716131316131314120
Selling, general & administrative555555555555
Other expenses0−14−17−16−13−110300−1211
Operating income−17−21−20−20−18−18−22−21−18−20−17−17
3−461−24−1−40000
Interest income111111111000
Interest expense00000000—000
Other non-operating income−34−6−12−4140000
Income before tax−14−24−14−19−20−14−23−25−18−20−16−17
Income tax expense000000—00—00
Net income from continuing operations−14−24−14−19−20−14—−25−18—−16−17
Net income−14−24−14−19−20−14−23−25−18−20−16−17
EPS, basic−$0.43−$0.74−$0.42−$0.56−$0.61−$0.41−$0.56−$0.68−$0.40−$0.41−$0.43−$0.43
EPS, diluted−$0.43−$0.74−$0.42−$0.56−$0.61−$0.41−$0.56−$0.68−$0.40−$0.41−$0.43−$0.43
Weighted average shares, basic333333333334373737373839
Weighted average shares, diluted333333333334373737373839
EBITDA−13−24−13−18−20−13−21−25−18−19−16−16
Depreciation & amortization111111111111
EBIT−14−24−14−19−20−14−22−25−18−20−16−17